Wegovy Pill Results: What the Trial Showed
Wegovy pill results: OASIS 4 trial weight loss, how it compares with the injection, side effects and early user reviews. Not medical advice.
Anonymous user report. Not medical advice. Peptides discussed are not FDA-approved for the uses described. Editorial process →
Short answer
In the OASIS 4 trial, adults with obesity or overweight taking the Wegovy pill lost on average about 16.6% of body weight over 64 weeks, versus about 2.7% on placebo, when results are counted for people who stayed on treatment. Weight loss accumulated over months rather than weeks. Gastrointestinal effects were the most common side effects. Averages hide wide individual variation, and trial participants also followed diet and activity programmes. Early real-world reviews are anecdotal; this site's semaglutide confessions mostly concern injections. Peptide Confessions does not publish dosing, timing, injection or sourcing guidance.
What users report here
Anonymous accounts are collected on the Semaglutide reports. They are personal stories, often with other compounds in the mix, not evidence of effect.
related peptides:
community guides:
More confessions from the archive
Community Q&A
- How much weight do people lose on the Wegovy pill?
- The pivotal trial averaged about 16.6% over 64 weeks among people who stayed on treatment. Individual results vary widely.
- Is the Wegovy pill as effective as the injection?
- Trial averages were in a similar range, but from separate studies.
- Does this page give dosing advice?
- Peptide Confessions does not publish dosing, timing, injection or sourcing guidance.
Sources
Anonymous first-hand reports plus sourced context — educational only, not medical advice. Editorial policy & corrections.